If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

Gregg Stone cast doubt on its reliability in trials, while David Cohen said QoL matters to patients and should be measured.

Merging interventional and AHFTC training programs would be a boon for patients and the HF subspecialty, experts argue.

Clyde Yancy talks to Priya Freaney and Nisha Parikh about the landscape of cardiovascular care for women and how it can be ...

Clyde Yancy, Roxana Mehran, and Howard Herrmann discuss strategies for increasing clinical trial enrollment among women, including targeting disease phenotypes and sex-specific trials. Sponsored by ...

Demystifying the AED, and training a generation of kids in their use, is key to prevent “catastrophic” sudden deaths in young ...

The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.

The complications portend a rise in the arrhythmia, and also in mortality, with an average time to event of 7 years.

The instructions for use have been updated to address issues that led to a greater risk of neurovascular events in an early ...

Much of the conversation at THT revolved around how use of the device would be handled outside of specialized centers.

Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

Using the BiovitalsHF software to personalize recommendations got more patients on all four pillars of therapy.